[시장보고서]종양 전사체학 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 종양 유형별, 기술별, 제품 유형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

종양 전사체학 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 종양 유형별, 기술별, 제품 유형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Tumor Transcriptomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tumor Type, By Technology, By Product, By Application, By End User, and By Region, Competition, 2020-2030F

상품코드 : 1878824

리서치사 : TechSci Research

발행일 : 2025년 11월

페이지 정보 : 영문 183 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,681,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,165,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,877,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 종양 전사체학 시장은 2024년에 60억 2,000만 달러로 평가되었으며, 2030년까지 CAGR 6.34%로 성장하여 87억 1,000만 달러에 달할 것으로 예측됩니다.

종양 전사체학은 암세포 내 리보핵산 전사체를 종합적으로 분석하는 기술로, 유전자 발현 패턴, 질병 분류, 진행에 대한 중요한 정보를 제공합니다. 이 시장의 확대는 주로 전 세계적으로 각종 암 질환의 유병률 증가와 유전체 시퀀싱 기술의 지속적인 발전에 의해 뒷받침되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	60억 2,000만 달러
시장 규모 : 2030년	87억 1,000만 달러
CAGR : 2025-2030년	6.34%
가장 빠르게 성장하는 부문	유방암
최대 시장	북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

시장 규모 및 예측
- 금액별
시장 점유율과 예측
- 종양 유형별(유방암, 폐암, 대장암, 전립선암, 악성 흑색종, 기타)
- 기술별(마이크로어레이, 실시간 정량, 중합효소 연쇄 반응(Q-PCR), 기타)
- 제품별(소모품, 기기, 소프트웨어·서비스)
- 용도별(진단·질환 프로파일링, Drug Discovery, 기타)
- 최종사용자별(바이오테크놀러지·제약 기업, 연구기관 및 학술기관, 기타)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 종양 전사체학 시장 전망

시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 종양 전사체학 시장 전망

시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 종양 전사체학 시장 전망

시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 종양 전사체학 시장 전망

시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 종양 전사체학 시장 전망

시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

인수합병
제품 출시
최근 동향

제13장 세계의 종양 전사체학 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협

제15장 경쟁 구도

Thermo Fischer Scientific, Inc.
Caris Life Sciences.
Illumina, Inc.
NanoString Technologies, Inc.
10x Genomics, Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche AG
Standard BioTools Inc.
Pacific Biosciences of California, Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global Tumor Transcriptomics Market, valued at USD 6.02 Billion in 2024, is projected to experience a CAGR of 6.34% to reach USD 8.71 Billion by 2030. Tumor transcriptomics involves the comprehensive analysis of ribonucleic acid transcripts within cancer cells, providing essential insights into gene expression patterns, disease classification, and progression. This market's expansion is primarily supported by the increasing global prevalence of various cancer types and continuous advancements in genomic sequencing technologies.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.02 Billion
Market Size 2030	USD 8.71 Billion
CAGR 2025-2030	6.34%
Fastest Growing Segment	Breast Cancer
Largest Market	North America

Key Market Drivers

The escalating global incidence of cancer serves as a primary catalyst for the expansion of the tumor transcriptomics market. As cancer rates continue to rise across diverse populations, there is a sustained demand for sophisticated diagnostic and prognostic tools capable of unraveling complex molecular signatures of various tumor types. Tumor transcriptomics offers unparalleled insights into gene expression patterns and disease progression, crucial for effective clinical management and treatment stratification. According to the International Agency for Research on Cancer, in February 2024, "Global cancer burden growing, amidst mounting need for services" article, in 2022 there were an estimated 20 million new cancer cases worldwide, highlighting the extensive patient population requiring advanced molecular profiling. This pervasive disease burden necessitates continuous innovation in transcriptomic analysis to provide actionable information for clinicians.

Key Market Challenges

The scarcity of professionals possessing specialized expertise in both molecular biology and the bioinformatics required for complex analysis represents a significant impediment to the Global Tumor Transcriptomics Market's expansion. These specialists are critical for interpreting the vast and intricate transcriptomic datasets, which are fundamental for precise disease classification, understanding progression, and guiding therapeutic strategies. Without sufficient qualified personnel, the advanced genomic sequencing technologies, despite continuous advancements, cannot be fully leveraged.

Key Market Trends

The emergence of spatial tumor transcriptomics for tissue analysis is significantly influencing the market by enabling researchers to precisely map gene expression within the architectural context of a tumor, providing insights into cellular interactions and disease microenvironments that bulk sequencing cannot. This technology is becoming crucial for understanding tumor heterogeneity and identifying novel biomarkers for targeted therapies. For example, Vizgen, a company at the forefront of this technology, announced the first global shipments of its MERSCOPE Ultra Platform in September 2024, delivering enhanced capabilities to leading research institutions worldwide to accelerate discoveries in spatial genomics. This advancement, which triples the imaging area of its predecessor to 3.0 cm2 on a single slide and offers faster imaging speeds, underscores the growing demand for high-resolution spatial multiomic analysis systems to propel foundational and clinical research.

Key Market Players

Thermo Fischer Scientific, Inc.
Caris Life Sciences.
Illumina, Inc.
NanoString Technologies, Inc.
10x Genomics, Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche AG
Standard BioTools Inc.
Pacific Biosciences of California, Inc.

Report Scope:

In this report, the Global Tumor Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tumor Transcriptomics Market, By Tumor Type:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Others

Tumor Transcriptomics Market, By Technology:

Microarray
Real-Time Quantitative
Polymerase Chain Reaction (Q-PCR)
Others

Tumor Transcriptomics Market, By Product:

Consumables
Instrument
Software & Services

Tumor Transcriptomics Market, By Application:

Diagnostics and Disease Profiling
Drug Discovery
Others

Tumor Transcriptomics Market, By End User:

Biotechnology & Pharmaceutical Companies
Research & Academic Institutions
Others

Tumor Transcriptomics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tumor Transcriptomics Market.

Available Customizations:

Global Tumor Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tumor Transcriptomics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others)
- 5.2.2. By Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Others)
- 5.2.3. By Product (Consumables, Instrument, Software & Services)
- 5.2.4. By Application (Diagnostics and Disease Profiling, Drug Discovery, Others)
- 5.2.5. By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Others)
- 5.2.6. By Region
- 5.2.7. By Company (2024)
5.3. Market Map

6. North America Tumor Transcriptomics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Tumor Type
- 6.2.2. By Technology
- 6.2.3. By Product
- 6.2.4. By Application
- 6.2.5. By End User
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Tumor Transcriptomics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Tumor Type
    - 6.3.1.2.2. By Technology
    - 6.3.1.2.3. By Product
    - 6.3.1.2.4. By Application
    - 6.3.1.2.5. By End User
- 6.3.2. Canada Tumor Transcriptomics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Tumor Type
    - 6.3.2.2.2. By Technology
    - 6.3.2.2.3. By Product
    - 6.3.2.2.4. By Application
    - 6.3.2.2.5. By End User
- 6.3.3. Mexico Tumor Transcriptomics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Tumor Type
    - 6.3.3.2.2. By Technology
    - 6.3.3.2.3. By Product
    - 6.3.3.2.4. By Application
    - 6.3.3.2.5. By End User

7. Europe Tumor Transcriptomics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Tumor Type
- 7.2.2. By Technology
- 7.2.3. By Product
- 7.2.4. By Application
- 7.2.5. By End User
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Tumor Transcriptomics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Tumor Type
    - 7.3.1.2.2. By Technology
    - 7.3.1.2.3. By Product
    - 7.3.1.2.4. By Application
    - 7.3.1.2.5. By End User
- 7.3.2. France Tumor Transcriptomics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Tumor Type
    - 7.3.2.2.2. By Technology
    - 7.3.2.2.3. By Product
    - 7.3.2.2.4. By Application
    - 7.3.2.2.5. By End User
- 7.3.3. United Kingdom Tumor Transcriptomics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Tumor Type
    - 7.3.3.2.2. By Technology
    - 7.3.3.2.3. By Product
    - 7.3.3.2.4. By Application
    - 7.3.3.2.5. By End User
- 7.3.4. Italy Tumor Transcriptomics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Tumor Type
    - 7.3.4.2.2. By Technology
    - 7.3.4.2.3. By Product
    - 7.3.4.2.4. By Application
    - 7.3.4.2.5. By End User
- 7.3.5. Spain Tumor Transcriptomics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Tumor Type
    - 7.3.5.2.2. By Technology
    - 7.3.5.2.3. By Product
    - 7.3.5.2.4. By Application
    - 7.3.5.2.5. By End User

8. Asia Pacific Tumor Transcriptomics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Tumor Type
- 8.2.2. By Technology
- 8.2.3. By Product
- 8.2.4. By Application
- 8.2.5. By End User
- 8.2.6. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Tumor Transcriptomics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Tumor Type
    - 8.3.1.2.2. By Technology
    - 8.3.1.2.3. By Product
    - 8.3.1.2.4. By Application
    - 8.3.1.2.5. By End User
- 8.3.2. India Tumor Transcriptomics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Tumor Type
    - 8.3.2.2.2. By Technology
    - 8.3.2.2.3. By Product
    - 8.3.2.2.4. By Application
    - 8.3.2.2.5. By End User
- 8.3.3. Japan Tumor Transcriptomics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Tumor Type
    - 8.3.3.2.2. By Technology
    - 8.3.3.2.3. By Product
    - 8.3.3.2.4. By Application
    - 8.3.3.2.5. By End User
- 8.3.4. South Korea Tumor Transcriptomics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Tumor Type
    - 8.3.4.2.2. By Technology
    - 8.3.4.2.3. By Product
    - 8.3.4.2.4. By Application
    - 8.3.4.2.5. By End User
- 8.3.5. Australia Tumor Transcriptomics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Tumor Type
    - 8.3.5.2.2. By Technology
    - 8.3.5.2.3. By Product
    - 8.3.5.2.4. By Application
    - 8.3.5.2.5. By End User

9. Middle East & Africa Tumor Transcriptomics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Tumor Type
- 9.2.2. By Technology
- 9.2.3. By Product
- 9.2.4. By Application
- 9.2.5. By End User
- 9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Tumor Transcriptomics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Tumor Type
    - 9.3.1.2.2. By Technology
    - 9.3.1.2.3. By Product
    - 9.3.1.2.4. By Application
    - 9.3.1.2.5. By End User
- 9.3.2. UAE Tumor Transcriptomics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Tumor Type
    - 9.3.2.2.2. By Technology
    - 9.3.2.2.3. By Product
    - 9.3.2.2.4. By Application
    - 9.3.2.2.5. By End User
- 9.3.3. South Africa Tumor Transcriptomics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Tumor Type
    - 9.3.3.2.2. By Technology
    - 9.3.3.2.3. By Product
    - 9.3.3.2.4. By Application
    - 9.3.3.2.5. By End User

10. South America Tumor Transcriptomics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Tumor Type
- 10.2.2. By Technology
- 10.2.3. By Product
- 10.2.4. By Application
- 10.2.5. By End User
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Tumor Transcriptomics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Tumor Type
    - 10.3.1.2.2. By Technology
    - 10.3.1.2.3. By Product
    - 10.3.1.2.4. By Application
    - 10.3.1.2.5. By End User
- 10.3.2. Colombia Tumor Transcriptomics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Tumor Type
    - 10.3.2.2.2. By Technology
    - 10.3.2.2.3. By Product
    - 10.3.2.2.4. By Application
    - 10.3.2.2.5. By End User
- 10.3.3. Argentina Tumor Transcriptomics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Tumor Type
    - 10.3.3.2.2. By Technology
    - 10.3.3.2.3. By Product
    - 10.3.3.2.4. By Application
    - 10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Tumor Transcriptomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Thermo Fischer Scientific, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Caris Life Sciences.
15.3. Illumina, Inc.
15.4. NanoString Technologies, Inc.
15.5. 10x Genomics, Inc.
15.6. Agilent Technologies, Inc.
15.7. Bio-Rad Laboratories, Inc.
15.8. F. Hoffmann-La Roche AG
15.9. Standard BioTools Inc.
15.10. Pacific Biosciences of California, Inc.